Stuvia.com - The Marketplace to Buy and Sell your Study
ss ss ss ss ss ss ss ss ss
Material
ADVANCED PHARMACOLOGY FOR ss ss ss
PRESCRIBERS1STEDITIONBYLUOK
ss s s s s s
AYINGO TESTBANK |2024UPDATE
ss ss s ss s s
, Stuvia.com - The Marketplace to Buy and Sell your Study
ss ss ss ss ss ss ss ss ss
Material
Table of Contents ss ss
Chapter 1: An Introduction to Evidence-Based Clinical Practice Guidelines................................... 3
s s ss s s s s s s s s s s ss
Chapter 2: Pharmacokinetics /Chapter3: Pharmacodynamics ............................................................... 13
s s ss s s ss
Chapter4: Pharmacogenetics and Pharmacogenomics ............................................................................ 25
ss s s s s
Chapter 5: Pharmacology Across the Life Span................................................................................. 30
s s ss s s s s ss ss
Chapter 6: Drug-Therapy Prescribing in Special Populations ............................................................ 36
s s ss s s ss s s ss
Chapter 7: Drug Development and Approval ...................................................................................... 45
s s ss ss s s s s
Chapter 8-Chapter 10: Foundations of Prescription Writing Chapter 9:
s s s s s s s s s s s s s s s s
ResponsibleControlled- Substance Prescribing Chapter 10: Antibiotic Stewardship ......................... 51
s s ss s s ss ss ss s s
Chapter 11: Applied Calculations for Prescribing .............................................................................. 58
s s ss s s ss s s
Chapter 12-: Promoting Adherence With Pharmacotherapy II: System-Specific and
s s s s s s s s s s s s s s s s
s Patient- Focused Prescribing Chapter 13: Pharmacotherapy for Ear, Nose, Mouth, andThroat
s ss s s ss s s ss ss s s s s s s s s
Conditions /Chapt er 14: Pharmacotherapy for Eye Conditions ........................................................ 67
s s s s ss ss ss ss ss s s
Chapter 15: Pharmacotherapy for Skin Conditions ............................................................................. 74
s s ss ss s s s s
Chapter 16: Pharmacotherapy for Neurologic Conditions .................................................................. 81
s s ss ss ss s s
Chapter 17: Pharmacotherapy for Cardiovascular Conditions ............................................................ 94
s s ss s s s s ss
Chapter 18: Pharmacotherapy for Respiratory Conditions ................................................................ 106
s s ss s s ss s s
Chapter 19: Pharmacotherapy for Gastrointestinal Conditions and Conditions RequiringNutritional Sup
ss ss ss ss ss ss ss ss ss
port ..........................................................................................................................................................117
s s
Chapter 20: Pharmacotherapy formGenitourinary Conditions ............................................................. 128
s s ss ss s s
Chapter 21: Pharmacotherapy for Renal, Acid–Base, Fluid, and Electrolyte Disorders .............. 133
ss ss ss s s s s s s s s s s s s
Chapter 22: Pharmacotherapy for Musculoskeletal and Rheumatologic Conditions ..................... 146
s s ss s s s s ss s s s s
Chapter 23: Therapeutic Applications of Immunology and Vaccines ........................................... 158
s s ss s s s s s s s s s s
Chapter 24: Pharmacotherapy for Endocrine Disorders .................................................................... 163
s s ss s s s s s s
Chapter 25: Pharmacotherapy for Hematologic Disorders ................................................................ 174
s s ss ss ss s s
Chapter 26: Hematology/Oncology and Supportive Care for the Nononcologist.......................... 190
s s ss s s s s s s ss s s ss
Chapter 27: Pharmacotherapy Related to Women’s Health Conditions........................................ 196
s s ss s s s s s s s s s s
Chapter 28: Pharmacotherapy Related to Men’s Health Conditions .............................................. 211
s s ss s s s s s s ss s s
Chapter 29: Pharmacotherapy Related to Transgender Care ........................................................... 217
s s ss s s s s s s ss
Chapter 30: Antimicrobial Pharmacotherapy ....................................................................................... 224
s s ss s s
Chapter 31: Antiretroviral Pharmacotherapy ........................................................................................ 235
s s ss ss
Chapter 32: Psychopharmacology and Integrative Health: Combined Treatment ofPsychiatric and
ss ss s s ss ss ss s s ss s s
Neur ocognitive Conditions .....................................................................................................................247
ss ss ss
Chapter 33: Pharmacotherapy for Pain Management........................................................................ 257
s s ss s s s s s s
Chapter 34: Substance Use Disorder III: Health Promotion and Maintenance............................ 267
s s ss s s s s s s ss s s s s s s
Chapter 35: Over-the-CountermMedications ........................................................................................... 283
s s ss
Chapter 36: Pharmacotherapy for Obesity .......................................................................................... 291
s s ss ss s s
, Stuvia.com - The Marketplace to Buy and Sell your Study
ss ss ss ss ss ss ss ss ss
Material
Chapter 1: An Introduction to Evidence-Based Clinical Practice Guidelines
s s s s s s s s s s s s s s s s
MULTIPLE CHOICE ss
• What is the primary purpose s s s s s s s s s s of s s the s s nursing assessment? s s
A. Identifyingmunderlying s s pathologic s s s s conditions
B. Assisting s s the s s physician s s in identifying s s s s medical s s conditions
C. Determining s s the patients mental status s s s s s s
D. Exploring patient s s s s responses s s to s s health s s problems
ANS:mD
A nursingmassessment is done to identify the patients response to
s s s s s s s s s s s s s s s s s s
health problems. Duringmthe nursing assessment phase, a
s s ss s s s s s s s s s s
comprehensive inform ation base is developed through a physical
s s s s ss s s s s s s s s s s s s
examination, nursing history, medication history, and professional
s s s s s s ss s s s s s s
observation. Identifying underlying pathologic conditions and
s s s s s s s s s s s s
assisting the physician in identifying medical conditions is not
s s s s s s s s s s s s ss s s s s
part of the nursing process. Determining the patients m ental
s s s s s s s s s s s s s s s s s s ss
status is one part of the nursing assessment, but it is
s s s s s s s s s s s s s s s s s s s s s s
s not the pri mary purpose.
s s s s s ss ss
DIF: Cognitive Level: Comprehension
ss ss ss
REF: dm 36 OBJ: 1 | 3 TOP:
ss s s s s s s s s s s s s s s
Nursin g Process Step: Assessment
s s ss ss ss ss
MSC: NCLEX Client Needs Category:
s s s s s s s s s s Health Promotion and s s s s s s Maintenance
• What is the basis s s s s s s s s of the NANDA I taxonomy?
s s s s ss s s
A. Functional s s health s s patterns
B. Human s s response s s patterns
C. Basic s s human s s needs
D. Pathophysiologic s s needs
ANS:mB
The NANDA I taxonomy identifies human response
s s s s s s s s s s s s
s patterns. Functi onal components of health patterns are limited
s s s ss s s s s s s s s s s s s
to activity, fluid volume, nutrition, self care, and sensory
s s s s s s s s ss s s s s s s s s
perception. Basic human needs compri se less than merely
s s s s s s s s s s s s s s s s s s
health patterns. Pathophysiologic needs are not par t of the
s s s s s s s s s s s s s s ss s s s s
scope of NANDA I.
s s s s s s ss
, Stuvia.com - The Marketplace to Buy and Sell your Study ss ss ss ss ss ss ss ss ss
Material
DIF: Cognitive Level: Knowledge RE
ss ss ss ss
F: pp. 37-38 OBJ: 5 TOP:
s s ss ss s s ss s s
Nursing Process Step: Diagnosis s s s s s s
MSC: NCLEX Client Needs Category: Physiological
s s s s s s s s s s s s Integrity
• Which task is included s s s s s s s s in the assessment step
s s s s s s s s of s s the s s nursing s s process?
A. Establishing s s patient s s goals/outcomes
B. Implementing s s the s s nursing care s s s s plan s s (NCP)
C. Measuring s s goal/outcome s s achievement
D. Collecting s s and s s communicating s s data
ANS: D s s
Data are collected and communicated in the assessment phase of
s s s s s s s s s s s s s s s s s s
the nur singmprocess. Establishingmgoals is the function of
s s s s ss s s s s s s s s s s
planning.
s s
Implementing the NCP is the function of implementation. Measuring out
s s s s s s s s s s s s s s s s s s
come achievement is the function of evaluation.
s s s s s s s s s s s s
DIF: Cognitive Level: s s s s
Comprehensio n REF: dm 36 OBJ: 2
s s s s ss ss ss ss ss
| 3 TOP: Nursi ng Process Step:
ss ss s s ss s s ss ss
Assessment
ss
MSC: NCLEX Client Needs Category:
s s s s s s s s s s Health Promotion and s s s s s s Maintenance
• Which statement s s s s regarding nursing s s s s diagnoses s s is s s accurate?
a. Nursing diagnoses remain the same s s s s s s s s s s for as s s s s long as the disease
s s s s s s s s is
present. s s
b. Nursing diagnoses s s s s are written to identify disease states.
s s s s s s s s s s
c. Nursing s s diagnoses s s describe s s patient problems s s s s that s s nurses s s treat.
d. Nursing diagnoses s s s s identify s s causes s s related s s to illness. s s
ANS:mC
Diagnostic statements identify problems a nurse is independently
s s s s s s s s s s s s s s
able to treat within the scope of professional practice. Nursing
s s s s ss s s s s s s s s s s s s s s
diagnoses vary with the changing condition of the patient. The
s s s s ss s s s s s s s s s s s s s s
response patterns are un ique to the patient and are not disease
s s s s s s s s ss s s s s s s s s s s s s s s
specific. Nursing diagnoses descr ibe the patients human response
s s s s s s s s ss s s s s s s s s
pattern.
s s
DIF: Cognitive s s s s Level: Comprehension s s
ss ss ss ss ss ss ss ss ss
Material
ADVANCED PHARMACOLOGY FOR ss ss ss
PRESCRIBERS1STEDITIONBYLUOK
ss s s s s s
AYINGO TESTBANK |2024UPDATE
ss ss s ss s s
, Stuvia.com - The Marketplace to Buy and Sell your Study
ss ss ss ss ss ss ss ss ss
Material
Table of Contents ss ss
Chapter 1: An Introduction to Evidence-Based Clinical Practice Guidelines................................... 3
s s ss s s s s s s s s s s ss
Chapter 2: Pharmacokinetics /Chapter3: Pharmacodynamics ............................................................... 13
s s ss s s ss
Chapter4: Pharmacogenetics and Pharmacogenomics ............................................................................ 25
ss s s s s
Chapter 5: Pharmacology Across the Life Span................................................................................. 30
s s ss s s s s ss ss
Chapter 6: Drug-Therapy Prescribing in Special Populations ............................................................ 36
s s ss s s ss s s ss
Chapter 7: Drug Development and Approval ...................................................................................... 45
s s ss ss s s s s
Chapter 8-Chapter 10: Foundations of Prescription Writing Chapter 9:
s s s s s s s s s s s s s s s s
ResponsibleControlled- Substance Prescribing Chapter 10: Antibiotic Stewardship ......................... 51
s s ss s s ss ss ss s s
Chapter 11: Applied Calculations for Prescribing .............................................................................. 58
s s ss s s ss s s
Chapter 12-: Promoting Adherence With Pharmacotherapy II: System-Specific and
s s s s s s s s s s s s s s s s
s Patient- Focused Prescribing Chapter 13: Pharmacotherapy for Ear, Nose, Mouth, andThroat
s ss s s ss s s ss ss s s s s s s s s
Conditions /Chapt er 14: Pharmacotherapy for Eye Conditions ........................................................ 67
s s s s ss ss ss ss ss s s
Chapter 15: Pharmacotherapy for Skin Conditions ............................................................................. 74
s s ss ss s s s s
Chapter 16: Pharmacotherapy for Neurologic Conditions .................................................................. 81
s s ss ss ss s s
Chapter 17: Pharmacotherapy for Cardiovascular Conditions ............................................................ 94
s s ss s s s s ss
Chapter 18: Pharmacotherapy for Respiratory Conditions ................................................................ 106
s s ss s s ss s s
Chapter 19: Pharmacotherapy for Gastrointestinal Conditions and Conditions RequiringNutritional Sup
ss ss ss ss ss ss ss ss ss
port ..........................................................................................................................................................117
s s
Chapter 20: Pharmacotherapy formGenitourinary Conditions ............................................................. 128
s s ss ss s s
Chapter 21: Pharmacotherapy for Renal, Acid–Base, Fluid, and Electrolyte Disorders .............. 133
ss ss ss s s s s s s s s s s s s
Chapter 22: Pharmacotherapy for Musculoskeletal and Rheumatologic Conditions ..................... 146
s s ss s s s s ss s s s s
Chapter 23: Therapeutic Applications of Immunology and Vaccines ........................................... 158
s s ss s s s s s s s s s s
Chapter 24: Pharmacotherapy for Endocrine Disorders .................................................................... 163
s s ss s s s s s s
Chapter 25: Pharmacotherapy for Hematologic Disorders ................................................................ 174
s s ss ss ss s s
Chapter 26: Hematology/Oncology and Supportive Care for the Nononcologist.......................... 190
s s ss s s s s s s ss s s ss
Chapter 27: Pharmacotherapy Related to Women’s Health Conditions........................................ 196
s s ss s s s s s s s s s s
Chapter 28: Pharmacotherapy Related to Men’s Health Conditions .............................................. 211
s s ss s s s s s s ss s s
Chapter 29: Pharmacotherapy Related to Transgender Care ........................................................... 217
s s ss s s s s s s ss
Chapter 30: Antimicrobial Pharmacotherapy ....................................................................................... 224
s s ss s s
Chapter 31: Antiretroviral Pharmacotherapy ........................................................................................ 235
s s ss ss
Chapter 32: Psychopharmacology and Integrative Health: Combined Treatment ofPsychiatric and
ss ss s s ss ss ss s s ss s s
Neur ocognitive Conditions .....................................................................................................................247
ss ss ss
Chapter 33: Pharmacotherapy for Pain Management........................................................................ 257
s s ss s s s s s s
Chapter 34: Substance Use Disorder III: Health Promotion and Maintenance............................ 267
s s ss s s s s s s ss s s s s s s
Chapter 35: Over-the-CountermMedications ........................................................................................... 283
s s ss
Chapter 36: Pharmacotherapy for Obesity .......................................................................................... 291
s s ss ss s s
, Stuvia.com - The Marketplace to Buy and Sell your Study
ss ss ss ss ss ss ss ss ss
Material
Chapter 1: An Introduction to Evidence-Based Clinical Practice Guidelines
s s s s s s s s s s s s s s s s
MULTIPLE CHOICE ss
• What is the primary purpose s s s s s s s s s s of s s the s s nursing assessment? s s
A. Identifyingmunderlying s s pathologic s s s s conditions
B. Assisting s s the s s physician s s in identifying s s s s medical s s conditions
C. Determining s s the patients mental status s s s s s s
D. Exploring patient s s s s responses s s to s s health s s problems
ANS:mD
A nursingmassessment is done to identify the patients response to
s s s s s s s s s s s s s s s s s s
health problems. Duringmthe nursing assessment phase, a
s s ss s s s s s s s s s s
comprehensive inform ation base is developed through a physical
s s s s ss s s s s s s s s s s s s
examination, nursing history, medication history, and professional
s s s s s s ss s s s s s s
observation. Identifying underlying pathologic conditions and
s s s s s s s s s s s s
assisting the physician in identifying medical conditions is not
s s s s s s s s s s s s ss s s s s
part of the nursing process. Determining the patients m ental
s s s s s s s s s s s s s s s s s s ss
status is one part of the nursing assessment, but it is
s s s s s s s s s s s s s s s s s s s s s s
s not the pri mary purpose.
s s s s s ss ss
DIF: Cognitive Level: Comprehension
ss ss ss
REF: dm 36 OBJ: 1 | 3 TOP:
ss s s s s s s s s s s s s s s
Nursin g Process Step: Assessment
s s ss ss ss ss
MSC: NCLEX Client Needs Category:
s s s s s s s s s s Health Promotion and s s s s s s Maintenance
• What is the basis s s s s s s s s of the NANDA I taxonomy?
s s s s ss s s
A. Functional s s health s s patterns
B. Human s s response s s patterns
C. Basic s s human s s needs
D. Pathophysiologic s s needs
ANS:mB
The NANDA I taxonomy identifies human response
s s s s s s s s s s s s
s patterns. Functi onal components of health patterns are limited
s s s ss s s s s s s s s s s s s
to activity, fluid volume, nutrition, self care, and sensory
s s s s s s s s ss s s s s s s s s
perception. Basic human needs compri se less than merely
s s s s s s s s s s s s s s s s s s
health patterns. Pathophysiologic needs are not par t of the
s s s s s s s s s s s s s s ss s s s s
scope of NANDA I.
s s s s s s ss
, Stuvia.com - The Marketplace to Buy and Sell your Study ss ss ss ss ss ss ss ss ss
Material
DIF: Cognitive Level: Knowledge RE
ss ss ss ss
F: pp. 37-38 OBJ: 5 TOP:
s s ss ss s s ss s s
Nursing Process Step: Diagnosis s s s s s s
MSC: NCLEX Client Needs Category: Physiological
s s s s s s s s s s s s Integrity
• Which task is included s s s s s s s s in the assessment step
s s s s s s s s of s s the s s nursing s s process?
A. Establishing s s patient s s goals/outcomes
B. Implementing s s the s s nursing care s s s s plan s s (NCP)
C. Measuring s s goal/outcome s s achievement
D. Collecting s s and s s communicating s s data
ANS: D s s
Data are collected and communicated in the assessment phase of
s s s s s s s s s s s s s s s s s s
the nur singmprocess. Establishingmgoals is the function of
s s s s ss s s s s s s s s s s
planning.
s s
Implementing the NCP is the function of implementation. Measuring out
s s s s s s s s s s s s s s s s s s
come achievement is the function of evaluation.
s s s s s s s s s s s s
DIF: Cognitive Level: s s s s
Comprehensio n REF: dm 36 OBJ: 2
s s s s ss ss ss ss ss
| 3 TOP: Nursi ng Process Step:
ss ss s s ss s s ss ss
Assessment
ss
MSC: NCLEX Client Needs Category:
s s s s s s s s s s Health Promotion and s s s s s s Maintenance
• Which statement s s s s regarding nursing s s s s diagnoses s s is s s accurate?
a. Nursing diagnoses remain the same s s s s s s s s s s for as s s s s long as the disease
s s s s s s s s is
present. s s
b. Nursing diagnoses s s s s are written to identify disease states.
s s s s s s s s s s
c. Nursing s s diagnoses s s describe s s patient problems s s s s that s s nurses s s treat.
d. Nursing diagnoses s s s s identify s s causes s s related s s to illness. s s
ANS:mC
Diagnostic statements identify problems a nurse is independently
s s s s s s s s s s s s s s
able to treat within the scope of professional practice. Nursing
s s s s ss s s s s s s s s s s s s s s
diagnoses vary with the changing condition of the patient. The
s s s s ss s s s s s s s s s s s s s s
response patterns are un ique to the patient and are not disease
s s s s s s s s ss s s s s s s s s s s s s s s
specific. Nursing diagnoses descr ibe the patients human response
s s s s s s s s ss s s s s s s s s
pattern.
s s
DIF: Cognitive s s s s Level: Comprehension s s
